Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:BEAM NASDAQ:GH NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.61-6.5%$11.94$3.98▼$13.68$1.92B1.931.76 million shs1.95 million shsBEAMBeam Therapeutics$20.60-4.4%$19.00$13.52▼$35.25$2.08B2.142.76 million shs2.44 million shsGHGuardant Health$54.90-3.3%$53.81$20.14▼$68.00$6.85B1.452.22 million shs2.78 million shsVCYTVeracyte$30.88-3.1%$27.71$22.61▼$47.32$2.43B2.07921,853 shs615,136 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%-1.87%-2.40%+22.19%+187.24%BEAMBeam Therapeutics0.00%-1.34%+16.85%+20.75%-14.59%GHGuardant Health0.00%-8.70%-9.05%+11.38%+120.75%VCYTVeracyte0.00%-4.78%+2.80%+16.79%+1.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.61-6.5%$11.94$3.98▼$13.68$1.92B1.931.76 million shs1.95 million shsBEAMBeam Therapeutics$20.60-4.4%$19.00$13.52▼$35.25$2.08B2.142.76 million shs2.44 million shsGHGuardant Health$54.90-3.3%$53.81$20.14▼$68.00$6.85B1.452.22 million shs2.78 million shsVCYTVeracyte$30.88-3.1%$27.71$22.61▼$47.32$2.43B2.07921,853 shs615,136 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%-1.87%-2.40%+22.19%+187.24%BEAMBeam Therapeutics0.00%-1.34%+16.85%+20.75%-14.59%GHGuardant Health0.00%-8.70%-9.05%+11.38%+120.75%VCYTVeracyte0.00%-4.78%+2.80%+16.79%+1.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.88Moderate Buy$12.38-1.86% DownsideBEAMBeam Therapeutics 3.08Buy$46.40125.24% UpsideGHGuardant Health 3.06Buy$58.246.08% UpsideVCYTVeracyte 2.70Moderate Buy$40.9032.45% UpsideCurrent Analyst Ratings BreakdownLatest VCYT, ADPT, BEAM, and GH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025GHGuardant HealthBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$65.00 ➝ $70.008/8/2025VCYTVeracyteMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetUnderweight$28.008/6/2025ADPTAdaptive BiotechnologiesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $14.008/6/2025ADPTAdaptive BiotechnologiesTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $15.008/6/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$13.00 ➝ $15.008/6/2025BEAMBeam TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$25.00 ➝ $21.007/31/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$57.00 ➝ $60.007/31/2025GHGuardant HealthRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$59.00 ➝ $61.007/21/2025BEAMBeam TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/14/2025GHGuardant HealthEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/18/2025ADPTAdaptive BiotechnologiesCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$178.96M10.73N/AN/A$1.37 per share9.20BEAMBeam Therapeutics$63.52M32.81N/AN/A$8.86 per share2.33GHGuardant Health$739.02M9.26N/AN/A($1.13) per share-48.58VCYTVeracyte$445.76M5.45$1.04 per share29.78$15.17 per share2.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.82N/AN/AN/A-59.07%-60.93%-23.03%11/6/2025 (Estimated)BEAMBeam Therapeutics-$376.74M-$4.50N/AN/AN/A-661.31%-43.15%-31.06%11/4/2025 (Estimated)GHGuardant Health-$436.37M-$3.35N/AN/AN/A-49.93%N/A-28.95%11/5/2025 (Estimated)VCYTVeracyte$24.14M$0.3393.5842.89N/A5.50%6.07%5.53%11/5/2025 (Estimated)Latest VCYT, ADPT, BEAM, and GH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ADPTAdaptive Biotechnologies-$0.24-$0.17+$0.07-$0.17$49.40 million$49.94 million8/5/2025Q2 2025BEAMBeam Therapeutics-$1.04-$1.00+$0.04-$1.00$13.29 million$8.47 million7/30/2025Q2 2025GHGuardant Health-$0.52-$0.44+$0.08-$0.80$211.19 million$232.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/ABEAMBeam Therapeutics$0.904.37%N/AN/A N/AGHGuardant HealthN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.842.75BEAMBeam TherapeuticsN/A6.756.75GHGuardant HealthN/A3.713.35VCYTVeracyteN/A5.435.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%BEAMBeam Therapeutics99.68%GHGuardant Health92.60%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%BEAMBeam Therapeutics3.50%GHGuardant Health6.10%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790152.27 million142.53 millionOptionableBEAMBeam Therapeutics510101.16 million97.62 millionOptionableGHGuardant Health2,021124.71 million117.10 millionNot OptionableVCYTVeracyte79078.67 million77.57 millionOptionableVCYT, ADPT, BEAM, and GH HeadlinesRecent News About These CompaniesVeracyte, Inc. $VCYT Stake Trimmed by Great Lakes Advisors LLCSeptember 13 at 4:19 AM | marketbeat.comVeracyte (NASDAQ:VCYT) CEO Sells 7,667 SharesSeptember 10, 2025 | marketbeat.comVeracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual MeetingSeptember 10, 2025 | finance.yahoo.comVeracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comMarc Stapley Sells 7,667 Shares of Veracyte (NASDAQ:VCYT) StockSeptember 9, 2025 | insidertrades.comVeracyte, Inc. (NASDAQ:VCYT) Receives $40.90 Average Target Price from AnalystsSeptember 9, 2025 | americanbankingnews.comVeracyte, Inc. $VCYT Stake Lifted by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comBridgeway Capital Management LLC Sells 41,300 Shares of Veracyte, Inc. $VCYTSeptember 8, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 8, 2025 | marketbeat.comRaymond James Financial Inc. Purchases 172,010 Shares of Veracyte, Inc. $VCYTSeptember 6, 2025 | marketbeat.comPDT Partners LLC Sells 27,566 Shares of Veracyte, Inc. $VCYTSeptember 5, 2025 | marketbeat.comMagnetar Financial LLC Invests $651,000 in Veracyte, Inc. $VCYTSeptember 3, 2025 | marketbeat.comTrexquant Investment LP Sells 10,790 Shares of Veracyte, Inc. $VCYTSeptember 3, 2025 | marketbeat.comHsbc Holdings PLC Buys 10,618 Shares of Veracyte, Inc. $VCYTSeptember 2, 2025 | marketbeat.comRafferty Asset Management LLC Has $3.29 Million Stock Position in Veracyte, Inc. $VCYTSeptember 1, 2025 | marketbeat.comNorthern Trust Corp Trims Stake in Veracyte, Inc. $VCYTSeptember 1, 2025 | marketbeat.comDriehaus Capital Management LLC Purchases 167,604 Shares of Veracyte, Inc. $VCYTAugust 31, 2025 | marketbeat.comRussell Investments Group Ltd. Sells 28,644 Shares of Veracyte, Inc. $VCYTAugust 31, 2025 | marketbeat.comNext Century Growth Investors LLC Lowers Stake in Veracyte, Inc. $VCYTAugust 30, 2025 | marketbeat.comVeracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceAugust 29, 2025 | businesswire.comVeracyte reports Phase 3 STAMPEDE trial finding published in CellAugust 28, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCYT, ADPT, BEAM, and GH Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$12.61 -0.88 (-6.52%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$12.90 +0.29 (+2.27%) As of 09/12/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Beam Therapeutics NASDAQ:BEAM$20.60 -0.95 (-4.41%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$20.61 +0.01 (+0.05%) As of 09/12/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Guardant Health NASDAQ:GH$54.90 -1.89 (-3.33%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$54.92 +0.02 (+0.05%) As of 09/12/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Veracyte NASDAQ:VCYT$30.88 -0.98 (-3.08%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$30.87 -0.01 (-0.03%) As of 09/12/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
